Nasdaq
$0.3920▲ 0.62%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $85.1MShares out 2.200M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
13- 1d agoAfter-hours26.10.24 06:03DEFA14AOther#●●●#●●●
Tenaya Therapeutics, Inc.
Tenaya Therapeutics will hold a special meeting of stockholders on December 9, 2026, to vote on a proposal for a reverse stock split. The proposal seeks authorization for the board of directors to effect a reverse stock split of all issued and outstanding common stock at a ratio ranging from 1-for-10 to 1-for-25.…more
$0.3920+0.62%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 1d agoAfter-hours26.10.24 05:47DEF 14AOther
Tenaya Therapeutics, Inc.
Tenaya Therapeutics will hold a special meeting of stockholders on December 9, 2026, to vote on a proposal for a reverse stock split. The proposal seeks authorization for the board of directors to implement a reverse stock split at a ratio ranging from 1-for-10 to 1-for-25 at their discretion.…more
$0.3920+0.62%vs prev closeView filingShare - 10.13After-hours26.10.14 05:42PRE 14AOther
Tenaya Therapeutics, Inc.
Tenaya Therapeutics will hold a special meeting of stockholders on December 9, 2026, to vote on a proposed reverse stock split. The board of directors is authorized to determine the final ratio within a range of 1-for-10 to 1-for-25 to address listing requirements and adjust share value.…more
$0.3920+0.62%vs prev closeView filingShare
12 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.14Pre-market26.09.14 21:30#●●●#●●●
Tenaya Therapeutics Receives FDA RMAT Designation for TN-401 Heart Disease Therapy…more
Tenaya Therapeutics' gene therapy candidate TN-401 has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. FDA. This designation, supported by positive interim clinical trial data, facilitates expedited development and regulatory review for the treatment of PKP2-associated ARVC.…more
$0.3920+0.62%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.3After-hours26.09.04 05:30
●●●●●●●● ●●●●● ●●●●●●
Tenaya Therapeutics announced its participation in the upcoming H.C. Wainwright and Morgan Stanley healthcare investor conferences in September. This event is for investor relations purposes and does not contain new material business developments.…more
$0.3920+0.62%vs prev close
1 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report